The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Open accessThe DOI matches its Crossref record; 119 of the 140 references it cites were found in a registry or an index; 9 of the 77 sources its claims cite were checked for support.
Abstract
OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.
Overview
CoChat Summary
TL;DR
This Endocrine Society guideline recommends case detection for Cushing's syndrome only in selected high-risk groups, initial testing with one of four high-accuracy tests, and confirmatory second testing before cause-directed evaluation. It emphasizes excluding exogenous glucocorticoids first and notes that most recommendations rest on very low- to low-quality evidence.
Key findings
- Exclude exogenous glucocorticoid exposure before biochemical testing (1QQQQ); test patients with multiple and progressive features, unusual features for age, children with decreasing height percentile and increasing weight, or adrenal incidentaloma compatible with adenoma, and recommend against widespread testing in other groups.
- Initial testing should use one of: urine free cortisol (at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test, or 48-h 2 mg/d dexamethasone suppression test; recommend against random serum cortisol/plasma ACTH, urinary 17-ketosteroids, insulin tolerance test, loperamide test, and cause-directed tests for initial diagnosis.
- Reported test performance includes late-night salivary cortisol sensitivity 92–100% and specificity 93–100%; pediatric UFC sensitivity about 89%; 1-mg DST at a 1.8 µg/dL cutoff sensitivity >95% with specificity 80%, rising to >95% specificity at a 5 µg/dL threshold; LDDST sensitivity 96% and specificity 70%; dexamethasone-CRH sensitivity 98% and specificity 60%.
- Special-population recommendations: use UFC and avoid dexamethasone testing in pregnancy; avoid dexamethasone testing with enzyme-inducing antiepileptics; suggest 1-mg overnight DST rather than UFC in severe renal failure; suggest UFC or midnight salivary cortisol rather than DSTs in suspected cyclic Cushing's; suggest 1-mg DST or late-night cortisol rather than UFC in adrenal incidentaloma.
Methods
- A six-member Task Force appointed by The Endocrine Society's Clinical Guidelines Subcommittee, including a chair, five additional experts, a methodologist, and a medical writer, received no corporate funding or remuneration; consensus was guided by systematic reviews and discussions and approved sequentially by Society bodies and members.
- Recommendations used the GRADE approach: strong recommendations phrased “we recommend” with number 1, weak recommendations “we suggest” with number 2; evidence quality ranged from QEEE (very low) to QQQQ (high), informed by best available research evidence and systematic reviews/meta-analyses of test accuracy.
- The guideline presents evidence, values, and remarks linked to each recommendation; technical remarks often reflect the panel's unsystematic observations applied to a typical patient.
Limitations
- Stated: the majority of recommendations are based on very low- to low-quality evidence, with limited data linking diagnostic strategies to patient-important outcomes and no higher-quality direct evidence available.
- Stated: published data often come from larger tertiary referral centers and may be biased toward more diagnostically challenging cases, higher pretest probability, and greater disease severity, potentially giving an overly sanguine view of test performance in unselected populations.
- Evident from the text: this is a consensus guideline rather than a primary study, and some technical recommendations rest on unsystematic panel observations; data on treating mild/subclinical Cushing's syndrome and adrenal incidentaloma are described as limited and conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study of 86 consecutive obese subjects referred to an endocrine clinic with diabetes mellitus, hypertension, and/or the polycystic ovary syndrome found a 5.8% incidence of Cushing's syndrome (35).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.3 Evidence
What the sources say
- Partly supportedcites [35] 35. Ness-Abramof R, Nabriski D, Apovian CM, Niven M, Weiss E, Shapiro MS, Shenkman L 2002 Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese. Obes Res 10:1217-1221 sourceExperimental — accuracy not yet measured
The Patients section describes 86 obese patients referred to an endocrine clinic, and the Results report five Cushing’s syndrome diagnoses—5/86, or approximately 5.8%, though the paper prints 5.7%. The copy does not say the patients were consecutive. It also reports that 51 had obesity alone, so diabetes, hypertension, and polycystic ovary disease do not describe the whole group. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The salivary glands express 11-hydroxysteroid dehydrogenase type 2 (11-HSD2), which converts the biologically active cortisol to inactive cortisone (75).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Remarks for late-night salivary cortisol
What the sources say
- Supportedcites [75] 75. Smith RE, Maguire JA, Stein-Oakley AN, Sasano H, Takahashi K, Fuku- shima K, Krozowski ZS 1996 Localization of 11-hydroxysteroid dehydro- genase type II in human epithelial tissues. J Clin Endocrinol Metab 81:3244 - 3248 source
The paper reports 11β-HSD2 in the ducts of human parotid and submandibular salivary glands (Abstract; Discussion, p. 3247). It describes the enzyme as inactivating glucocorticoids and discusses salivary cortisol-to-cortisone ratios (Introduction; Discussion, p. 3247), supporting the stated function. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, the evidence in adults suggests that the accuracy of this test is similar to that of UFC (2).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Evidence for late-night salivary cortisol
What the sources say
- Supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 source
Table 3 (Conclusions; page unavailable) reports broadly similar pooled diagnostic likelihood ratios for midnight salivary cortisol and UFC. The Summary of findings notes that evidence for salivary cortisol is more limited, consistent with the citing sentence’s cautious wording. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the assay upper limit of normal is used as a criterion, the overall evidence supports the diagnostic accuracy of UFC in adults suspected of having Cushing's syndrome (2,51).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.1 Evidence for use of UFC
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Summary of findings says UFC has substantial evidence supporting its use to detect Cushing’s syndrome, and the pooled results table reports diagnostic accuracy across 14 UFC studies. The Subgroup analyses section identifies an assay-upper-limit cutoff, but the reported UFC estimate is pooled across studies rather than shown specifically for that cutoff. The Conclusions also limit the apparent accuracy to referral practices enriched with patients with Cushing’s syndrome; performance in usual clinical practice remains unclear. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [51] 51. Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cav- agnini F 2007 Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab 92:4123- 4129 source
The UFC results (p. 2) report 91.2% specificity in Cushing’s syndrome suspects when values above the assay’s reference range were considered abnormal. The Discussion (p. 5) identifies that threshold as the assay’s upper limit of normal and describes UFC as having superior diagnostic performance. The study assessed specificity, rather than diagnostic accuracy across all measures. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The four recommended tests have acceptable diagnostic accuracy when the suggested cutoff points are used (2,30).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4 Evidence
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Conclusions state that commonly used tests appear highly accurate in referral practices with samples enriched for Cushing’s syndrome, but that their performance in usual clinical practice is unclear. The Data extraction section says the review used cutoffs chosen by the primary studies, selecting those with the best performance when several were available; it does not establish accuracy specifically at the suggested cutoff points. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [30] 30. Batista DL, Riar J, Keil M, Stratakis CA 2007 Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics 120: e575-e586 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 3 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, accurate serum cortisol measurement is essential for the correct diagnosis and management of adrenal pathologies.”
From Serum cortisol: an up-to-date assessment of routine assay performance (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3,14,23)”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some authors have proposed higher (3 or 8 mg) dexamethasone doses (40,46,54,56), which however did not show a better performance (14,23,66).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measured
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“biochemical hypercortisolism is present in a large fraction (up to 10%).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > Subsequent evaluation
“3.9.1 We suggest the additional use of the dexamethasone-CRH test or the midnight serum cortisol test in specific situations (Fig. 1, 1QEEE).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS
“strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“with expertise in development and implementation of evidencebased guidelines (1).”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationGold, P. W., Loriaux, D. L., Roy, A., Kling, M. A., Calabrese, J. R., Kellner, C. H., Nieman, L. K., Post, R. M., Pickar, D., Gallucci, W., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605223142101 · Cited by 766
Self-citationThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundTESTS OF PITUITARY-ADRENAL SUPPRESSIBILITY IN THE DIAGNOSIS OF CUSHING'S SYNDROME*
LIDDLE, G. W. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-12-1539 · Cited by 735
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“These data are consistent with the increased cardiovascular mortality and morbidity reported in patients with iatrogenic Cushing’s syndrome secondary to the chronic use of synthetic corticosteroids (15).”
ResultMeasurements of Serum Free Cortisol in Critically Ill Patients
Hamrahian, A. H., Oseni, T. S., & Arafah, B. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa020266 · Cited by 726 · cited 1×
“are associated with decreased serum cortisol values (39, 46).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622 · cited 2×
“0-fold, compared with the general population (4, 5).”
BackgroundIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619 · cited 6×
“Because some patients with Cushing’s disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion J Clin Endocrinol Metab, May 2008, 93(5):1526–1540 jcem.”
BackgroundInfluential
Cited by
Items 501–600 of 2,716
Endocrine incidentalomas—challenges imposed by incidentally discovered lesions
Vassiliadi, D. A., & Tsagarakis, S. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.92 · Cited by 39
Vassiliadi, D. A., Ntali, G., Stratigou, T., Adali, M., & Tsagarakis, S. (2011) · Endocrine · doi:10.1007/s12020-011-9490-1 · Cited by 36
Ohno, Y., Sone, M., Inagaki, N., Kawashima, A., Takeda, Y., Yoneda, T., Kurihara, I., Itoh, H., Tsuiki, M., Ichijo, T., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14601 · Cited by 38
Targeted Mutational Analysis of Cortisol-Producing Adenomas
Rege, J., Hoxie, J. M., Liu, C.-J., Cash, M. N., Luther, J. M., Gellert, L. L., Turcu, A. F., Else, T., Giordano, T. J., Udager, A. M., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab682 · Cited by 43
Pituitary adenomas evade apoptosis via noxa deregulation in Cushing’s disease
Asuzu, D. T., Alvarez, R., Fletcher, P. A., Mandal, D., Johnson, K. R., Wu, W., ELKAHLOUN, A. G., Clavijo, P. E., Allen, C. T., Maric, D., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111223 · Cited by 37
“0 mg/24H forR18 year-olds) or low-dose dexamethasone suppression testing (1mg overnight or 2mg over 48 h) (Lonser et al., 2017; Nieman et al., 2008).”
Self-citationSubclinical hypercortisolism in adrenal incidentaloma
Debono, M., & Newell-Price, J. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000151 · Cited by 36
“The Endocrine Society guidelines [12] and an Italian Association of Clinical”
BackgroundInfluentialSelf-citationReimondo, G., Puglisi, S., Zaggia, B., Basile, V., Saba, L., Perotti, P., Francia, S. D., Volante, M., Zatelli, M. C., Cannavò, S., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0452 · Cited by 38
“Therefore, we have also assessed salivary cortisol in our patients, as cortisol levels in saliva reflect free cortisol (23) and may give a more accurate estimate of cortisol secretion independently from variation in CBG.”
Effect of cabergoline monotherapy in Cushing’s disease: an individual participant data meta-analysis
Palui, R., Sahoo, J., Kamalanathan, S., Kar, S. S., Selvarajan, S., & Durgia, H. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0936-7 · Cited by 38
Large Genomic Aberrations in Corticotropinomas Are Associated With Greater Aggressiveness
Tatsi, C., Pankratz, N., Lane, J., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02164 · Cited by 36
Seltzer, J. A., Lucas, J. W., Commins, D., Lerner, O., Lerner, A., Carmichael, J. D., & Zada, G. (2015) · Neurosurgical FOCUS · doi:10.3171/2014.10.focus14685 · Cited by 35
Dalmazi, G. D., Quinkler, M. O., Deutschbein, T., Prehn, C. P., Rayes, N., Kroiß, M., Berr, C., Stalla, G. K., Faßnacht, M., Adamski, J., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0109 · Cited by 43
“The first group consisted of patients with CS (n=49), diagnosed according to current guidelines (7) and included 27 with ACTH-dependent CS.”
BackgroundMethodKannankeril, J., Carroll, T., Findling, J. W., Javorsky, B., Gunsolus, I. L., Phillips, J., & Raff, H. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa107 · Cited by 36
“Late-night salivary cortisol (LNSC) measured by immunoassay is a useful and simple means to screen patients for suspected hypercortisolism and has been recommended by expert guidelines as an important first-line diagnostic test [24, 25].”
BackgroundMethodSelf-citationGenetics of Cushing 's disease
Simon, J., & Theodoropoulou, M. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13148 · Cited by 38
“Partial resistance to negative glucocorticoid feedback is a hallmark of Cushing's disease.(51) Initial reports suggested that mutations in the”
BackgroundIncreased Risk of Vertebral Fractures in Patients With Mild Autonomous Cortisol Secretion
Favero, V., Eller-Vainicher, C., Morelli, V., Cairoli, E., Salcuni, A. S., Scillitani, A., Corbetta, S., Casa, S. D., Muscogiuri, G., Persani, L., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad560 · Cited by 44
Advances in electrochemical biosensor design for the detection of the stress biomarker cortisol
Weber, C. J., Clay, O. M., Lycan, R. E., Anderson, G. K., & Simoska, O. (2023) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-023-05047-1 · Cited by 38
“This stress biomarker is instrumental in the function of metabolic pathways throughout the body, serving as a messenger to elicit physiological responses such as wound healing and immunity [12, 13].”
Prague, J., May, S., & Whitelaw, B. (2013) · BMJ · doi:10.1136/bmj.f945 · Cited by 48
Velghe, S., Capiau, S., & Stove, C. P. (2016) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2016.01.030 · Cited by 43
Chronic Central Serous Chorioretinopathy as a Presenting Symptom of Cushing Syndrome
van Dijk, E. H. C., Dijkman, G., Biermasz, N. R., van Haalen, F. M., Pereira, A. M., & Boon, C. J. F. (2016) · European Journal of Ophthalmology · doi:10.5301/ejo.5000790 · Cited by 35
“Endocrinologic analysis for the presence and etiology of CS was performed according to the Endocrine Society clinical guidelines (20).”
MethodMelmed, S. K., & Kleinberg, D. L. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00009-2 · Cited by 38
Cushing’s syndrome: a model for sarcopenic obesity
Drey, M., Berr, C., Reincke, M., Fazel, J., Seißler, J., Schopohl, J., Bidlingmaier, M., Zopp, S., Reisch, N., Beuschlein, F., et al. (2017) · Endocrine · doi:10.1007/s12020-017-1370-x · Cited by 38
Kyo, C., Usui, T., Kosugi, R., Torii-Hanakita, M., Yonemoto, T., Ogawa, T., Kotani, M., Tamura, N., Yamamoto, Y. L., Katabami, T., et al. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00210 · Cited by 38
“A diagnosis of CS was established by an expert endocrinologist at the time of presentation according to the Endocrine Society clinical guidelines for the diagnosis of CS [27].”
MethodKageyama, K., Asari, Y., Sugimoto, Y., Niioka, K., & Daimon, M. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej19-0239 · Cited by 31
A New Insight into the Surgical Treatment of Primary Macronodular Adrenal Hyperplasia
Tanno, F. Y., Srougi, V., Almeida, M. Q., Yamauchi, F. I., Coelho, F. M. A., Nishi, M. Y., Zerbini, M. C. N., Soares, I. S. C., Pereira, M. A. A., Charchar, H. L. S., et al. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa083 · Cited by 40
“Alencar GA, Fragoso MC, Yamaga LY, Lerario AM, Mendonca BB. (18)F-FDG-PET/CT imaging of ACTH-independent macronodular adrenocortical hyperplasia (AIMAH) demonstrating increased (18)F-FDG uptake.”
BackgroundInfluentialAssessment of glucocorticoid therapy with salivary cortisol in secondary adrenal insufficiency
Ceccato, F., Albiger, N., Reimondo, G., Frigo, A. C., Ferasin, S., Occhi, G., Mantero, F., Terzolo, M., & Scaroni, C. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0534 · Cited by 35
“Since a normal night-time cortisol value excludes hypercortisolism (32), the F 14 salivary cortisol could be a useful marker of glucocorticoid excess in AI.”
Dennedy, M. C., Smith, D., O'Shea, D. B., & McKenna, T. J. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0576 · Cited by 40
Raff, H. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.10.005 · Cited by 34
da Silva-Júnior, R. M. P., Bueno, A. C., Martins, C. S., Coeli‐Lacchini, F. B., Ozaki, J. G. O., Almeida-e-Silva, D. C., Marrero-Gutiérrez, J., dos Santos, A. C., García-Peral, C., Machado, H. R., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac703 · Cited by 37
Endocrine disorders associated with obesity
Park, H. K., & Ahima, R. S. (2023) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2023.102394 · Cited by 38
Adipose tissue in cortisol excess: What Cushing’s syndrome can teach us?
Bavaresco, A., Mazzeo, P., Lazzara, M., & Barbot, M. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116137 · Cited by 45
Skin manifestations of hormone-secreting tumors
Jabbour, S. A. (2010) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2010.01369.x · Cited by 33
“Screening and diagnosis of Cushing’s syndrome is very complex and necessitates a referral to an endocrinologist (7).”
BackgroundPituitary Tumor Management in Pregnancy
Araújo, P. B., Neto, L. V., & Gadelha, M. R. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.10.015 · Cited by 37
“According to the guidelines for diagnosis of CS, the use of this test during pregnancy should not be preferred because of false-positive results due to blunted response to dexamethasone.(63)”
BackgroundMethodThe use of mass spectrometry to improve the diagnosis and the management of the HPA axis
Monaghan, P. J., Keevil, B. G., & Trainer, P. J. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-013-9240-1 · Cited by 28
Subclinical Cushing’s syndrome: Current concepts and trends
Zografos, G. N., Perysinakis, I., & Vassilatou, E. (2014) · HORMONES · doi:10.14310/horm.2002.1506 · Cited by 35
Carrasco, C. A., García, M., Goycoolea, M., Cerda, J., Bertherat, J., Padilla, O., Meza, D., Wohllk, N., & Quiroga, T. (2012) · Endocrine · doi:10.1007/s12020-012-9597-z · Cited by 34
Advances in Bioanalytical Techniques to Measure Steroid Hormones in Serum
French, D. (2016) · Bioanalysis · doi:10.4155/bio-2015-0025 · Cited by 38
Constantinescu, G. A., Langton, K., Conrad, C., Amar, L., Assié, G., Gimenez‐Roqueplo, A., Blanchard, A., Larsen, C. K., Mulatero, P., Williams, T. A., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa423 · Cited by 33
“Diagnosis was based on results of conventional diagnostic testing following current guidelines (12-14).”
MethodCeccato, F., Tizianel, I., Vedolin, C. K., Boscaro, M., Barbot, M., & Scaroni, C. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa564 · Cited by 33
Frequently asked questions and answers (if any) in patients with adrenal incidentaloma
Ceccato, F., Barbot, M., Scaroni, C. M., & Boscaro, M. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01615-3 · Cited by 38
Chan, L. F., Vaidya, M., Westphal, B., Allgrove, J., Martin, L., Afshar, F., Hindmarsh, P. C., Savage, M. O., Grossman, A. B., & Storr, H. L. (2011) · Hormone Research in Paediatrics · doi:10.1159/000324419 · Cited by 37
Self-citationHöybye, C., Ragnarsson, O., Jönsson, P. J., Koltowska-Häggström, M., Trainer, P., Feldt-Rasmussen, U., & Biller, B. M. K. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0836 · Cited by 34
Self-citationEnhanced oxidative stress and platelet activation in patients with Cushing's syndrome
Karamouzis, I., Berardelli, R., D’Angelo, V., Fussotto, B., Zichi, C., Giordano, R., Settanni, F., Maccario, M., Ghigo, E., & Arvat, E. (2014) · Clinical Endocrinology · doi:10.1111/cen.12524 · Cited by 40
Daniel, E., & Newell-Price, J. D. C. (2013) · Medicine · doi:10.1016/j.mpmed.2013.06.007 · Cited by 37
Self-citationGeer, E. B., Shafiq, I., Gordon, M. B., Bonert, V., Ayala, A., Swerdloff, R. S., Katznelson, L., Lalazar, Y., Manuylova, E., Pulaski-Liebert, K. J., et al. (2017) · Endocrine Practice · doi:10.4158/ep171787.or · Cited by 33
“CD diagnosis was confirmed by each site’s principal investigator and the Endocrine Society guidelines (11).”
MethodSelf-citationBiochemical diagnosis of Cushing’s disease: Screening and confirmatory testing
Petersenn, S. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101519 · Cited by 33
Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes
Buse, J. B., Kahn, S. E., Aroda, V. R., Auchus, R. J., Bailey, T. S., Bancos, I., Busch, R. S., Christofides, E. A., DeFronzo, R. A., Eilerman, B., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2841 · Cited by 47
Self-citationNakajima, Y., Okamura, T., Gohko, T., Satoh, T., Hashimoto, K., Shibusawa, N., Ozawa, A., Ishii, S., Tomaru, T., Horiguchi, K., et al. (2014) · Endocrine Journal · doi:10.1507/endocrj.ej14-0282 · Cited by 34
“Funder J, Carey R, Fardella C, Gomez-Sanchez C, Mantero F, et al. (2008) Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline.”
BackgroundMethodInfluentialThe Clinical Features and Molecular Mechanisms of ACTH-secreting Pancreatic Neuroendocrine Tumors
Zhang, C., Jin, J., Xie, J., Ye, L., Su, T., Jiang, L., Zhou, W., Jiang, Y., Wu, L., Wang, T., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa507 · Cited by 37
Evaluation and Treatment of Patients With Hypercortisolism: A Review
Miller, B. S., & Auchus, R. J. (2020) · JAMA Surgery · doi:10.1001/jamasurg.2020.3280 · Cited by 37
Castro, M. A., Valderrábano, P., Escobar-Morreale, H. F., Hanzu, F. A., & Casals, G. (2020) · Endocrine · doi:10.1007/s12020-020-02544-6 · Cited by 36
Arioli, F., Gamberini, M. C., Pavlović, R., Cesare, F. D., Draghi, S., Bussei, G., Mungiguerra, F., Casati, A., & Fidani, M. (2022) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-022-04249-3 · Cited by 38
“In patients with this syndrome, cortisol concentration is higher than in healthy people [7].”
BackgroundMethodPrediction of Vertebral Fractures in Patients With Monolateral Adrenal Incidentalomas
Morelli, V., Eller-Vainicher, C., Palmieri, S., Cairoli, E., Salcuni, A. S., Scillitani, A., Carnevale, V., Corbetta, S., Arosio, M., Della Casa, S., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1423 · Cited by 33
Molecular Derangements and the Diagnosis of ACTH-Dependent Cushing’s Syndrome
Nieman, L. K. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab046 · Cited by 33
“The remaining unbound (free) fraction is biologically active and diffuses into target tissues, where it (1) exerts metabolic effects, (2) is metabolized (eg, renal inactivation into cortisone by 11βHSD2 or additional hepatic conversions), (3) is incorporated into growing hair, or (4) is excreted in sweat, urine, or fe…”
BackgroundMethodInfluentialSelf-citationAssessment of mild autonomous cortisol secretion among incidentally discovered adrenal masses
Yozamp, N., & Vaidya, A. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101491 · Cited by 33
Seltzer, J. A., Ashton, C. E., Scotton, T. C., Pangal, D. J., Carmichael, J. D., & Zada, G. (2015) · Neurosurgical FOCUS · doi:10.3171/2014.10.focus14683 · Cited by 33
Bours, S., van den Bergh, J. P., van Geel, T. A. C. M., & Geusens, P. (2014) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000074 · Cited by 37
“Several guidelines recommend screening for hypercortisolism in patients with unexplained osteoporosis [78,79].”
BackgroundFein, H. G., Vaughan, T. B., Kushner, H., Cram, D., & Nguyen, D. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0059-5 · Cited by 32
“Background Endogenous Cushing’s syndrome (CS), a complex metabolic disorder resulting from prolonged exposure to elevated cortisol, is associated with substantial morbidity and mortality, particularly in relation to cardiovascular events [1–4].”
Cushing’s disease: Results of treatment and factors affecting outcome
Ammini, A. C., Bhattacharya, S., Sahoo, J. P., Philip, J., Tandon, N., Goswami, R., Jyotsna, V. P., Khadgawat, R., Chumber, S., Seth, A., et al. (2011) · HORMONES · doi:10.14310/horm.2002.1312 · Cited by 34
“2pmol/L).(6,18) These patients underwent high dose dexamethasone suppression test (HDDST) (2mg dexamethasone tablet every 6hr for 48 hours (greater than 80% reduction in cortisol values being considered suppressed).”
BackgroundRitvonen, E., Karppinen, A., Sintonen, H., Vehkavaara, S., Kivipelto, L., Roine, R. P., Niemela, M. R., & Schalin‐Jäntti, C. (2014) · Clinical Endocrinology · doi:10.1111/cen.12550 · Cited by 33
Dynamics of salivary cortisol in chronic kidney disease patients at stages 1 through 4
Cardoso, E. M. D. L., Arregger, A. L., Budd, D., Zucchini, A., & Contreras, L. N. (2016) · Clinical Endocrinology · doi:10.1111/cen.13023 · Cited by 35
de Araújo, L. J. T., Lerário, A. M., de Castro, M., Martins, C. S., Bronstein, M. D., Machado, M. C., Trarbach, E. B., & Fragoso, M. C. B. V. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00055 · Cited by 35
Corssmit, E. P. M., & Dekkers, O. M. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000528 · Cited by 59
Adrenocortical hyperplasia: a review of clinical presentation and imaging
Morani, A. C., Jensen, C. T., Habra, M. A., Agrons, M. M., Menias, C. O., Wagner‐Bartak, N. A., Shaaban, A. M., Roman-Colon, A. M., & Elsayes, K. M. (2019) · Abdominal Radiology · doi:10.1007/s00261-019-02048-6 · Cited by 33
“The presence of hypercortisolism is established by measuring 24 h urine free cortisol, dexamethasone suppression tests and/or measuring late night salivary cortisol [13].”
MethodPituitary Physiology and Diagnostic Evaluation
Kaiser, U. B., & Ho, K. K. Y. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00008-3 · Cited by 49
Korneeva, Y. A., & Simonova, N. N. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17217759 · Cited by 40
“The cortisol level in saliva does not depend on the volume and rate of its secretion, which is of fundamental importance in interpreting the results [50,51].”
Hidden hypercortisolism: a too frequently neglected clinical condition
Giovanelli, L., Aresta, C., Favero, V., Bonomi, M., Cangiano, B., Eller-Vainicher, C., Grassi, G., Morelli, V., Pugliese, F., Falchetti, A., et al. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01484-2 · Cited by 39
Oda, S., Ashida, K., Uchiyama, M., Sakamoto, S., Hasuzawa, N., Nagayama, A., Wang, L., Nagata, H., Sakamoto, R., Kishimoto, J., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab450 · Cited by 40
Heyn, J., Geiger, C., Hinske, L. C., Briegel, J., & Weis, F. C. (2011) · Pituitary · doi:10.1007/s11102-011-0314-3 · Cited by 32
“Diagnostic tests are based on demonstration of excessive cortisol secretion, loss of circadian rhythm, and abnormal regulation of hypothalamo-pituitary-axis [ 8 ].”
BackgroundMethodNew and Emerging Syndromes due to Neuroendocrine Tumors
Vinik, A. I., & Gonzales, M. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.12.010 · Cited by 34
Clinical characteristics of pain in patients with pituitary adenomas
Dimopoulou, C., Athanasoulia, A. P., Hanisch, E., Held, S., Sprenger, T., Toelle, T. R., Roemmler-Zehrer, J., Schopohl, J., Stalla, G. K., & Sievers, C. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0375 · Cited by 40
Tripodi, A., Ammollo, C. T., Semeraro, F., Colucci, M., Malchiodi, E., Verrua, E., Ferrante, E., Arnaldi, G., Trementino, L., Padovan, L., et al. (2016) · Endocrine · doi:10.1007/s12020-016-1027-1 · Cited by 33
Steffensen, C., Pereira, A. M., Dekkers, O. M., & Jørgensen, J. O. L. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0434 · Cited by 39
Biphenyl based stationary phases for improved selectivity in complex steroid assays
Lindner, J. M., Vogeser, M., & Grimm, S. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.04.020 · Cited by 34
Cortisol overproduction results from DNA methylation of CYP11B1 in hypercortisolemia
Kometani, M., Yoneda, T., Demura, M., Koide, H., Nishimoto, K., Mukai, K., Gómez-Sánchez, C. E., Akagi, T., Yokota, T., Horike, S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11435-2 · Cited by 42
Dickson, P. V., Kim, L., Yen, T. W. F., Yang, A. D., Grubbs, E. G., Patel, D., & Solórzano, C. C. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6749-2 · Cited by 33
Mechanism, diagnosis, and treatment of cyclic Cushing’s syndrome: A review
Cai, Y., Ren, L., Tan, S.-W., Liu, X., Li, C., Gang, X., & Wang, G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113301 · Cited by 43
Wagenmakers, M. A. E. M., Roerink, S. H. P. P., Gil, L., Plantinga, T. S., Smit, J. W. A., Netea-Maier, R. T., & Hermus, A. R. (2014) · Clinical Endocrinology · doi:10.1111/cen.12639 · Cited by 35
Novel Insights in the Diagnosis of Cushing’s Syndrome
Alexandraki, K., & Grossman, A. B. (2010) · Neuroendocrinology · doi:10.1159/000314295 · Cited by 35
Selective Glucocorticoid Receptor (GR-II) Antagonist Reduces Body Weight Gain in Mice
Asagami, T., Belanoff, J. K., Azuma, J., Blasey, C. M., Clark, R. D., & Tsao, P. S. (2011) · Journal of Nutrition and Metabolism · doi:10.1155/2011/235389 · Cited by 32
“The insulin resistance seen in Cushing’s syndrome causes its major symptoms (obesity, glucose intolerance, hypertension, and dyslipidemia); it is thought that a similar mechanism is responsible for the metabolic syndrome [4, 5], although patients who have the metabolic syndrome by definition do not have ACTH or cortis…”
The New Molecular Landscape of Cushing's Disease
Sbiera, S., Deutschbein, T., Weigand, I., Reincke, M., Faßnacht, M., & Allolio, B. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.08.003 · Cited by 32
“The diagnosis relies on confirmation of inappropriately elevated ACTH levels and concomitant cortisol excess [5–7].”
BackgroundWang, L., Li, N., Yao, X., Chang, G., Zhang, D., Heizhati, M., Wang, M., Luo, Q., & Kong, J. (2017) · BioMed Research International · doi:10.1155/2017/8295010 · Cited by 33
Liu, Z., Zhang, X., Wang, Z., You, H., Li, M. L., Feng, F., & Jin, Z. (2020) · Scientific Reports · doi:10.1038/s41598-020-71628-0 · Cited by 32
Salivary Stress/Immunological Markers in Crohn’s Disease and Ulcerative Colitis
Finamore, A., Peluso, I., & Cauli, O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228562 · Cited by 37
“The use of saliva for diagnostic purposes has several advantages, and it is already currently used to diagnose several diseases, such as neurological diseases [7], Cushing’s syndrome [8,9], human immunodeficiency virus (HIV) [10], cancer [11], and for the follow-up of several pathologies.”
BackgroundMetabolic and Endocrine Toxicities of Mitotane: A Systematic Review
Bianchini, M., Puliani, G., Chiefari, A., Mormando, M., Lauretta, R., & Appetecchia, M. (2021) · Cancers · doi:10.3390/cancers13195001 · Cited by 38
“Otherwise, salivary cortisol is unaffected by CBG levels and could be an index of free cortisol [48,49]; it is, therefore, theoretically better in patients treated with mitotane, even if the data are scanty.”
BackgroundAzorín, C., Benedé, J. L., & Chisvert, A. (2022) · Analytica Chimica Acta · doi:10.1016/j.aca.2022.340627 · Cited by 35
Atkinson, B., & Mullan, K. R. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04033.x · Cited by 31
Adrenal Disorders in Pregnancy
Abdelmannan, D. K., & Aron, D. C. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2011.09.001 · Cited by 35
“The biochemical diagnosis of Cushing syndrome is challenging in the best of circumstances.(2,26) Pregnancy only complicates the diagnosis.”
Friedman, T. C., Ghods, D. E., Shahinian, H. K., Zachery, L., Shayesteh, N., Seasholtz, S., Zuckerbraun, E., Lee, M. L., & McCutcheon, I. E. (2010) · Hormone and Metabolic Research · doi:10.1055/s-0030-1263128 · Cited by 31
“Cushing’s syndrome was excluded by lack of progression of symptoms (for at least 12 months following evaluation) and less than 2 different positive biochemical tests [6].”
BackgroundMethodInfluentialAdrenal adenomas, subclinical hypercortisolism, and cardiovascular outcomes
Dalmazi, G. D., & Pasquali, R. (2015) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000153 · Cited by 33
Antonelli, G., Artusi, C., Marinova, M., Brugnolo, L., Zaninotto, M., Scaroni, C. M., Gatti, R. D., Mantero, F., & Plebani, M. (2013) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2013-0471 · Cited by 32
“Pathological samples were obtained from 26 patients (7 males, 19 females; age range, 8–84 years) with a diagnosis of CS according to a recent guideline [19] and recruited from the endocrinology operative unit.”
Altered spontaneous brain activity in Cushing's disease: a resting-state functional MRI study
Jiang, H., He, N., Sun, Y., Jian, F., Bian, L., Shen, J.-K., Yan, F., Pan, S., & Sun, Q. (2016) · Clinical Endocrinology · doi:10.1111/cen.13277 · Cited by 35
Yang, Y., Xiao, M., Song, Y., Tang, Y., Luo, T., Yang, S., He, W., Cheng, Q., Ma, L., Zhang, Y., et al. (2019) · Endocrine · doi:10.1007/s12020-019-02022-8 · Cited by 38
Inferior petrosal sinus sampling in Cushing’s syndrome: usefulness and pitfalls
Vassiliadi, D. A., Mourelatos, P., Kratimenos, T., & Tsagarakis, S. (2021) · Endocrine · doi:10.1007/s12020-021-02764-4 · Cited by 31
Do patients with type 2 diabetes mellitus have an increased prevalence of Cushing’s syndrome?
Krarup, T., Krarup, T., & Hagen, C. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2262 · Cited by 30
“Algorithm for testing patients suspected of having Cushing’s syndrome [19].”
BackgroundInfluentialNotch1 pathway in adrenocortical carcinomas: correlations with clinical outcome
Ronchi, C. L., Sbiera, S., Altieri, B., Steinhauer, S., Wild, V., Bekteshi, M., Kroiß, M., Faßnacht, M., & Allolio, B. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0163 · Cited by 33
Findling, J. W., Fleseriu, M., Newell-Price, J., Petersenn, S., Pivonello, R., Kandra, A., Pedroncelli, A. M., & Biller, B. M. K. (2016) · Endocrine · doi:10.1007/s12020-016-0978-6 · Cited by 30
Self-citationEndocrine Hypertension: A Practical Approach
Pappachan, J. M., & Buch, H. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_26 · Cited by 37
Martel‐Duguech, L., Alonso‐Jiménez, A., Bascuñana, H., Díaz‐Manera, J., Llauger, J., Nuñez‐Peralta, C., Biagetti, B., Montesinos, P., Webb, S. M., & Valassi, E. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz329 · Cited by 36
Bengtsson, D., Ragnarsson, Ó., Berinder, K., Dahlqvist, P. M., Engström, B. E., Ekman, B., Höybye, C., Burman, P., & Wahlberg, J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab079 · Cited by 34
“CD diagnosis were made according to local routines at each university hospital and included typical signs/symptoms and the conventional biochemical tests of CD (21).”
MethodSteroid profiling in the diagnosis of mild and overt Cushing’s syndrome
Athimulam, S., Grebe, S. K. G., & Bancos, I. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101488 · Cited by 34
“Patients may present with recent onset, or worsening of hypertension, diabetes mellitus type 2, dyslipidemia, osteoporosis, depression, or anxiety(11).”
BackgroundMethodHe, H., Dai, J., Shen, Z., Zhu, Y., Sun, F., Shao, Y., Rong-ming, Z., Wang, H., Rui, W., & Zhong, S. (2012) · World Journal of Surgery · doi:10.1007/s00268-012-1509-0 · Cited by 30
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M.
- Affiliations
- National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Medical College of Wisconsin (US)
- University of Sheffield (GB)
- Queen Mary University of London (GB)
- University of Birmingham (GB)
- Mayo Clinic (V.M.M.), Rochester, Minnesota 55905
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1526-1540
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2386281
- OpenAlex
- W1990995386
- Cited by
- 2,718
- References
- 140
- Citations by year
- 2026: 159 · 2025: 173 · 2024: 173 · 2023: 148 · 2022: 212 · 2021: 199 · 2020: 195 · 2019: 165 · 2018: 150 · 2017: 148 · 2016: 158 · 2015: 156 · 2014: 134 · 2013: 139 · 2012: 114
- FWCI
- 70.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diagnosis, hypercortisolism, adrenal incidentaloma, dexamethasone suppression test, late-night salivary cortisol, urine cortisol
- MeSH terms
- Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Saliva, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.